- Presentation highlights potential of ATOR-4066 to induce strong anti-tumor responses in patients with CEACAM5-expressing tumors
- Data strongly support further development of ATOR-4066 towards the clinic
- Data further validate Neo-X-Prime™, Alligator’s platform for 3rd generation conditional CD40 agonists
LUND, Sweden I April 18, 2023 I Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the company presented a poster on ATOR-4066, a Neo-X-Prime™ bispecific antibody (bsAb), at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida.
The presentation, entitled “ATOR-4066, a Neo-X-Prime™ bispecific antibody targeting CD40 and CEA, activates myeloid cells in primary human tumors in vitro and induces anti-tumor immunity in vivo”, highlights how ATOR-4066 has the potential to induce strong anti-tumor responses in patients with carcinoembryonic antigen 5 (CEACAM5)-expressing tumors.
CEACAM5, a well described clinical target for cancer therapy, is a glycoprotein that is overexpressed on the cell surface of many cancers including colorectal, gastric, pancreatic, and non-small cell lung cancer, with limited expression in normal adult tissue. Thus, it is an ideal target for a tumor-directed bispecific conditional CD40 agonist like ATOR-4066.
The data demonstrate CEACAM5 expression in relevant indications and how ATOR-4066 induces:
- CEACAM5-conditional CD40-activation of tumor-infiltrating immune cells in patient-derived dissociated tumor samples from indications with high CEACAM5 expression, including colorectal and gastric cancer
- co-localization of CEACAM5-expressing tumor debris and CD40-expressing antigen presenting cells
- strong in vivo anti-tumor efficacy and induction of immunological memory
“We are excited to be presenting new data from our novel Neo-X-Prime approach at this year’s AACR meeting,” said Søren Bregenholt, CEO of Alligator Bioscience. “We have already shown that simultaneously targeting CD40 and tumor associated antigens leads to superior anti-tumor immunity. These new data further demonstrate the ability of ATOR-4066 to remodel the immune microenvironment and, as it continues to show great potential in inducing strong anti-tumor responses in CEACAM5-expressing tumors, we remain committed to advancing ATOR-4066 towards the clinic.”
Poster Presentation Details
Abstract Number: 2939
Title: ATOR-4066, a Neo-X-Prime™bispecific antibody targeting CD40 and CEO, activates myeloid cells in primary human tumors in vitro and induces anti-tumor immunity in vivo
Date/Time: Monday 17 April, 2023, 1.30 – 5.00 pm EDT
Session: PO.IM01.12 – Therapeutic Antibodies 2
Presenter: Anette Sundstedt, Principal Scientist, Alligator Bioscience
Location: Orange County Convention Center, Poster Section 23, Poster Board 2939
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.
Alligator Bioscience’s shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.
For more information, please visit alligatorbioscience.com.
SOURCE: Alligator Bioscience
Post Views: 936
- Presentation highlights potential of ATOR-4066 to induce strong anti-tumor responses in patients with CEACAM5-expressing tumors
- Data strongly support further development of ATOR-4066 towards the clinic
- Data further validate Neo-X-Prime™, Alligator’s platform for 3rd generation conditional CD40 agonists
LUND, Sweden I April 18, 2023 I Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the company presented a poster on ATOR-4066, a Neo-X-Prime™ bispecific antibody (bsAb), at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida.
The presentation, entitled “ATOR-4066, a Neo-X-Prime™ bispecific antibody targeting CD40 and CEA, activates myeloid cells in primary human tumors in vitro and induces anti-tumor immunity in vivo”, highlights how ATOR-4066 has the potential to induce strong anti-tumor responses in patients with carcinoembryonic antigen 5 (CEACAM5)-expressing tumors.
CEACAM5, a well described clinical target for cancer therapy, is a glycoprotein that is overexpressed on the cell surface of many cancers including colorectal, gastric, pancreatic, and non-small cell lung cancer, with limited expression in normal adult tissue. Thus, it is an ideal target for a tumor-directed bispecific conditional CD40 agonist like ATOR-4066.
The data demonstrate CEACAM5 expression in relevant indications and how ATOR-4066 induces:
- CEACAM5-conditional CD40-activation of tumor-infiltrating immune cells in patient-derived dissociated tumor samples from indications with high CEACAM5 expression, including colorectal and gastric cancer
- co-localization of CEACAM5-expressing tumor debris and CD40-expressing antigen presenting cells
- strong in vivo anti-tumor efficacy and induction of immunological memory
“We are excited to be presenting new data from our novel Neo-X-Prime approach at this year’s AACR meeting,” said Søren Bregenholt, CEO of Alligator Bioscience. “We have already shown that simultaneously targeting CD40 and tumor associated antigens leads to superior anti-tumor immunity. These new data further demonstrate the ability of ATOR-4066 to remodel the immune microenvironment and, as it continues to show great potential in inducing strong anti-tumor responses in CEACAM5-expressing tumors, we remain committed to advancing ATOR-4066 towards the clinic.”
Poster Presentation Details
Abstract Number: 2939
Title: ATOR-4066, a Neo-X-Prime™bispecific antibody targeting CD40 and CEO, activates myeloid cells in primary human tumors in vitro and induces anti-tumor immunity in vivo
Date/Time: Monday 17 April, 2023, 1.30 – 5.00 pm EDT
Session: PO.IM01.12 – Therapeutic Antibodies 2
Presenter: Anette Sundstedt, Principal Scientist, Alligator Bioscience
Location: Orange County Convention Center, Poster Section 23, Poster Board 2939
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.
Alligator Bioscience’s shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.
For more information, please visit alligatorbioscience.com.
SOURCE: Alligator Bioscience
Post Views: 936
